Brookline Capital Markets initiated coverage on Marker Therapeutics (NASDAQ:MRKR), a company focused on developing T cell-based immunotherapies for cancer, with a Buy rating and a 12-to-18-month price ...

Patients treated in community settings were more likely to be older, less likely to be White, and had worse survival rates, ...

With positive mid-stage results in marginal zone lymphoma, Bristol Myers Squibb could soon add a new indication for the CAR T ...

Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand its reach in B-cell cancers.

With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types. | With another trial win, Bristol Myers Squibb is ...

Squibb announced the Phase 2 TRANSCEND FL trial evaluating Breyanzi, or lisocabtagene maraleucel, in adult patients with ...

Introduction Blood cancer diagnostics refers to the process of detecting and identifying cancers that affect the blood, bone marrow, and lympha ...

Lymphoma cancer is also among the top 10 types of cancer detected among Malaysians. The PAL Scheme provides free second-line ...

A new study reveals that modifying the CUL5 gene enhances CAR-T cell therapy for leukemia and lymphoma. This improves cell ...

Researchers have identified a method to enhance the effectiveness of a promising cancer treatment. They found that modifying a specific gene improves the ability of immune cells to combat cancer for ...

The FDA made strides in R/R T-cell lymphoma and breast cancer. An AI tool aids pathologists and other positive updates in gastric cancer and NSCLC.

Treatments are the same as cancer sufferers but they don't receive the same support, a mother says.